熱門資訊> 正文
Autonomix报告胰腺癌治疗疼痛减轻后股价上涨
2024-09-09 21:21
- Autonomix Medical (NASDAQ:AMIX) stock rose about 5.4% premarket after it announced preliminary results from the first five “lead-in” patients in the ongoing trial evaluating the safety and effectiveness of delivering transvascular energy to mitigate pancreatic cancer pain.
- Responders experienced a pain reduction from a pre-procedure pain score of 8 to a pain score of 1.33 at 4-6 weeks post-procedure.
- 60% of patients responded with a mean 6.67 or 83% reduction of pain on the VAS pain scale at 4-6 weeks post-procedure.
- Reduction of pain score occurred simultaneously as the subject’s underlying disease (pancreatic cancer tumor) continued to grow.
- The company said it is beneficial for patients who are considered end of life, given their advanced stage of disease.
- Source: Press Release
More on Autonomix Medical, Inc.
- IPO Roundup: Pershing Square, Actuate Therapeutics and more
- Autonomix appoints Brad Hauser as CEO
- Historical earnings data for Autonomix Medical, Inc.
- Financial information for Autonomix Medical, Inc.
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
